Receptor Life Sciences
Healthcare Services · Washington, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1200 5th Ave Ste 1400, Seattle, Washingt...Phone Number
(206) 483-2730Website
www.receptorlife.comRevenue
<$5 MillionIndustry
ZI Rank: 2
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
1
2
2
3
2
About Receptor Life Sciences
Receptor Life Sciences is a pharmaceutical company that applies FDA-approved drug-delivery technologies to develop innovative therapies to address central nervous system disorders that have few safe and effective treatments.Explore more
Receptor Life Sciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Receptor Life Sciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Receptor Life Sciences had a recent Job posting/layoffs
Check out if Receptor Life Sciences is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Receptor Life Sciences has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Receptor Life Sciences has new funding data
Earning: See what the market has to say on Receptor Life Sciences recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Receptor Life Sciences
Product Launch: Get notified when Receptor Life Sciences launches new products
Website visits: Recent activity has been detected on your website
Receptor Life Sciences, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Receptor Life Sciences
Compare insights from companies similar to Receptor Life Sciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Receptor Life Sciences
<$5M
11-50
Private
$39.7M
2015
TC
Traci CarmanFounder & Chief Financial Officer, Amp & Director, Amp
Company Profile Activity
Activity Insights
Receptor Life Sciences is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
Receptor Life Sciences is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about Receptor Life Sciences.
Receptor Life Sciences financials insights
Gather financial insights about Receptor Life Sciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series A
$39.7M
Receptor Life Sciences Tech Stack
A closer look at the technologies used by Receptor Life Sciences
See more technologies
Most Recent Scoops
Funding
Left Company
Executive Move
New Hire
Executive Move
Project
Product Development, Compliance
Receptor Life Sciences News & Media
Inhaled Dry Powder CBD For Epileptic Seizures: Receptor Life Sciences' FDA Drug Application
Receptor Life Sciences (RLS), a pharmaceutical company developing innovative therapies to address central nervous system disorders, recently announced it’s expanding the potential clinical utility of RLS103, a dry powder inhaled cannabidiol (CBD) into epilepsy treatment. read moreReceptor Life Sciences Opens Second Investigational New Drug (IND) Application with FDA for RLS103 (Inhaled Dry Powder CBD) for the Treatment of Rapid Epileptic Seizure Termination (REST)
SEATTLE--(BUSINESS WIRE)--Receptor Life Sciences (RLS), a pharmaceutical company developing innovative therapies to address central nervous system disorders, is expanding the potential clinical utility of RLS103 into epilepsy. A proof-of-concept clinical safety and efficacy study in epilepsy will be conducted under a second, recently opened IND application. The Phase 1b randomized, double-blind, placebo-controlled, crossover study will evaluate RLS103 in patients with photosensitive epilepsy asReceptor Life Sciences Announces First Patient Dosed with RLS103 (Inhaled Dry Powder CBD) in Phase 1b/2a Clinical Study in Acute Anxiety within Social Anxiety Disorder
SEATTLE--(BUSINESS WIRE)--Receptor Life Sciences (RLS), a clinical-stage pharmaceutical company developing innovative therapies to address central nervous system disorders, announced that the first patient has been dosed in its Phase 1b/2a clinical safety, tolerability, and efficacy study evaluating RLS103 in adult patients with acute anxiety within social anxiety disorder (SAD). RLS103, a dry powder inhaled cannabidiol (CBD), uses an inhalation formulation technology coupled with a breath-poweReceptor Life Sciences Secures $9.7 Million Financing to Advance RLS103 (Inhaled Dry Powder CBD) into Clinical Trials
SEATTLE--(BUSINESS WIRE)--Receptor Life Sciences (RLS), a pharmaceutical company developing innovative therapies to address central nervous system disorders, today announced the closing of a $9.7 million Series A-1 financing. The financing was led by Granite Point Capital, with participation from existing Series A and a syndicate of new investors. RLS will use the proceeds from the financing to advance RLS103 through proof-of-concept clinical safety and efficacy studies. RLS103, a dry powder in
Read more news
Top Healthcare Services Companies
Frequently Asked Questions Regarding Receptor Life Sciences
Sign Up For FreeTo access detailed company insights
Receptor Life Sciences is a pharmaceutical company that applies FDA-approved drug-delivery technologies to develop innovative therapies to address central nervous system disorders that have few safe and effective treatments.... Read More
